3 completed, 2 terminated. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Terminated 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow JNJ-40346527: new trials by email Literature Review of JNJ-40346527 trials Research Report on JNJ-40346527
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MIcroglial Colony Stimulating Factor-1 Receptor (CSF1R) in Alzheimer's Disease JNJ-40346527, Placebo - Alzheimer Disease, Mild Cognitive Impairment | Phase 1 | Terminated | University of Oxford | 2 | 2021-04-07 | 2024-05-09 |
| JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia Edicotinib, Pharmacokinetic Study - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 2 | Terminated | OHSU Knight Cancer Institute | 3 | 2018-10-05 | 2021-12-02 |
| Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer Daratumumab, FMS Inhibitor JNJ-40346527, Radical Prostatectomy - Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8 | Phase 1 | Completed | M.D. Anderson Cancer Center | 33 | 2017-06-07 | 2024-05-03 |
| A Study of JNJ-40346527 in Patients With Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug Therapy JNJ-40346527, Placebo - Arthritis, Rheumatoid | Phase 2 | Completed | Janssen Research & Development, LLC | 96 | 2012-07-01 | 2014-04-08 |
| A Single and Multiple Dose Study to Explore the Safety Of JNJ-40346527 In Healthy Volunteers JNJ-40346527/Placebo, JNJ-40346527 - Health | Phase 1 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 120 | 2010-01-01 | 2013-09-04 |
Alzheimer Disease (1) · Arthritis, Rheumatoid (1) · Cognitive Dysfunction (1) · Leukemia, Myeloid, Acute (1) · Prostatic Neoplasms (1)
Janssen Research & Development, LLC (1) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1) · M.D. Anderson Cancer Center (1) · OHSU Knight Cancer Institute (1) · University of Oxford (1)
United States (2) · Argentina (1) · Belgium (1) · Bulgaria (1) · Chile (1) · Czechia (1) · Hungary (1) · Poland (1) · Russia (1) · Singapore (1) · South Korea (1) · Ukraine (1) · United Kingdom (1)
Elie Traer, MD (1) · Sumit K Subudhi (1) · Vanessa Raymont (1)
2018 (1), P30CA016672 (1)